3 Earnings Reports That Caught My Attention Last Week: Akorn, Inc. (AKRX), Clean Energy Fuels Corp. (CLNE)

Page 1 of 2

As first-quarter earnings begin to wind down, I can’t help but point out that the majority of earnings reports we’ve covered over the past year have been better than expected. With so many companies reporting during the weeks that comprise earnings season, it’s easy for some earnings reports to fall through the cracks.

Each week for the past year, I’ve taken a look at three companies that could be worth further research after either beating or missing their profit expectations. Today, we’ll take a gander at three more companies that reported earnings last week. They may have slid under your radar, but they deserve a look.

Company Consensus EPS Reported EPS Surprise
Akorn, Inc. (NASDAQ:AKRX) $0.12 $0.13 8%
Clean Energy Fuels Corp. (NASDAQ:CLNE) ($0.22) ($0.23) (5%)
J.C. Penney Company, Inc. (NYSE:JCP) ($0.18) ($1.95) (983%)

Source: Yahoo! Finance.

Akorn
In January I took a closer look at the ups and downs of the generic drug sector and highlighted Akorn and Teva Pharmaceutical Industries Ltd (ADR) as my top two choices. My reasoning was primarily because they’re a hybrid type of pharmaceutical company — relying on their own branded drugs as well as generic drugs. Akorn certainly didn’t make me look bad in the first reported quarter since I made that claim.

In the fourth quarter, Akorn, Inc. (NASDAQ:AKRX) reported a 68% increase in revenue to $71.5 million as adjusted EPS jumped to $0.13 from $0.11 in the previous year. Growth came from acquisitions, such as assets from Kilitch Drugs in India, which expanded its generic injectable line, as well as from selling more organic compounds. What’s more, these results were on top of the downtime caused by Hurricane Sandy at its ophthalmic factory in New Jersey.

Akorn also noted in January that it anticipates bringing a combination of 39 branded and generic drugs to market between 2013 and 2015 with a total market value of approximately $3 billion, meaning we’re just seeing the tip of the iceberg. Even with the margin pressures often associated with generics, Akorn, Inc. (NASDAQ:AKRX) only saw its gross margin dip by a measly 20 basis points to 58% for the year. As I’ve said before, Akorn is far from cheap, but this is the type of hybrid growth I’d consider paying a premium for.

Clean Energy Fuels
On paper, Clean Energy Fuels Corp. (NASDAQ:CLNE)’s story continues to make a lot of sense. As President Obama moves the U.S. toward energy independence, it would seem only logical that we’d turn our attention to the most abundant natural resource right at our feet: natural gas. However, Clean Energy Fuels’ bottom-line results, as well as other factors, don’t bode well for its shareholders.

For the quarter, Clean Energy Fuels reported a 15% increase in sales as it delivered 29% more gallons of compressed, liquefied, and renewable natural gas. Still, the company managed to lose $0.23 on an adjusted basis compared to just $0.21 during the year-ago period.

The two primary problems with Clean Energy Fuels Corp. (NASDAQ:CLNE)’s strategy are that it doesn’t have the proper infrastructure in place (i.e., fueling stations) to promote widespread natural gas vehicle usage, and that many trucking fleets are still relatively new and not in need of spending millions to overhaul their fleet with natural gas engines. Take Marten Transport, Ltd (NASDAQ:MRTN), a trucking company specializing in temperature-sensitive hauling, for example. Marten’s year-end results in January show that its tractor and trailer fleet averaged just 2.0 and 2.2 years in age. This is a company that’ll be utilizing its current fleet for years and, I believe, represents the norm in the trucking sector. Clean Energy will need to sit on its hands until the next major replacement cycle in the trucking sector occurs, which bodes poorly for any chance of near-term profitability.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Top 10 Highest Paying Jobs in the World

Most Expensive Day-Care in New York City

The 10 Cheapest Places to Retire Abroad

Top 10 Most Expensive Luxury Cars in the World – 2014

Killer Small Business Ideas

The 50 Best Personal Finance Blogs

Most Expensive Apartments in New York City

Bloodiest UFC Fights Ever Fought

Most Expensive Rum Brands in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!